BofA Securities analyst Tazeen Ahmad raised the price target on Ascendis Pharma (NASDAQ: ASND) to $292.00 (from $262.00) while maintaining a Buy rating.

The analyst commented, "ASND reported 4Q25 Yorvipath sales of €187mn, highlighting >5.4K US scripts have been written since launch by over >2.4K unique US prescribers in 2025. We expect to see some seasonality headwind in 1Q related to insurance reset and currently model 1Q sales of €199.7mn (+7% q/q, cons: $209.7mn). On the 1Q call, we look for color on expectation for sales rebound in 2Q as well as comfort with expectation for >€1bn sales for FY26 (BofA: €1.08bn). We highlight mgmt has been signaling to overall steady Yorvipath growth from FY25 sales as they target €5bn in total product revenue by 2030 with primary share from Yorvipath. We also conducted a physician survey in 1Q that continued to highlight bullish long-term signals for the launch with respondents estimating up to 52% of their patients could be on Yorvipath at peak (see more inside). We reiterate our Buy with new $292 (see model changes)."